HTML
-
Plasma samples were collected from individuals diagnosed with HIV-1 infection in Sichuan province from 2011 to 2012. A total of 375 sequences of HIV-1 pol region that were verified as CRF07_BC by sequence analysis were successfully obtained, with 104 from therapy -naive patients and 271 from ART-failure patients. The demographics of these participants are summarized in Table 1. The median ages of the therapy-naïve and ARTfailure patients were 32 years (interquartile range 14-50 years) and 36 years (interquartile range 7-72 years), respectively. Males predominated in the study population (74.04% of therapy-naive and 71.23% of ART-failure individuals). Consistent with previously reported HIV-1 transmission routes in Sichuan, intravenous drug use and sexual conduct were the most common transmission routes in the current study. The average viral load was 4.59 lg copies/mL (interquartile range 2.89-6.74 lg copies/mL) in the ART-naive population and 4.51 lg copies/mL (interquartile range 1.70-6.27 lg copies/mL) in the ART-failure population.
Characteristic Patients ART naive
(n=104)ART failure
(n=271)Age, years 32(14–50) 36(7–72) Sex Male 77(74.04) 193(71.23) Female 27(25.96) 78(28.78) Viral load, RNA, lg copies/mL 4.59(2.89–6.74) 4.51(1.70–6.27) Route of HIV infection Intravenous drug use 82(78.85) 109(40.22) Homosexual sex 22(21.15) 19(7.01) Heterosexual sex – 137(50.55) MTCT – 5(3.68) Other/unknown – 1(0.74) Duration of ART, years – 1.4(0.3–6) ART regimen(current used) 3TC – 1(0.37) AZT – 1(0.37) d4T – 1(0.37) 3TC/AZT/NVP – 157(57.93) 3TC/d4T/NVP – 68(25.09) 3TC/EFV/AZT – 16(5.90) 3TC/EFV/d4T – 8(2.95) 3TC/AZT/LPV/r – 1(0.37) 3TC/TDF/EFV – 15(5.54) d4T/3TC/AZT/NVP – 3(1.11%) Results are presented as n (%) or median (interquartile range). Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; LPV/r, lopinavir with ritonavir; MTCT, mother-to-child transmission; NVP, nevirapine; TDF, tenofovir. Table 1. Demographic characteristics of study participants with HIV-1 CRF07_BC
ART was provided free of charge by the Chinese government. Lamivudine (3TC)/zidovudine (AZT)/nevirapine (NVP) was the most common regimen in ARTfailure individuals (57.93%), as shown in Table 1. The proportion of individuals treated with 3TC/stavudine/NVP, 3TC/efavirenz/AZT and 3TC/tenofovir/efavirenz was 25.09%, 5.90%, and 5.54%, respectively. However, only one participant in the current study received protease inhibitor therapy with lopinavir and ritonavir.
-
The presence of mutations in the HIV-1 pol gene was evaluated by comparing the sequences against the Stanford University HIV Drug Resistance Database to identify the known mutations related to drug resistance. In the ART-failure group, 31.73% of participants harbored at least one drug-resistance mutation, compared with only one participant (1%) in the ART-naive group. In this patient, the major mutation M46L was seen in the protease region, which reduced susceptibility to indinavir, nelfinavir, fosamprenavir, lopinavir, and atazanavir. All drug-resistance mutations identified in ART-failure individuals were in the RT region (Table 2). The most prevalent mutation was K103N (45.01%), followed by M184V/I (35.88%), Y 181C (17.33%), G190S/A (15.88%), Y188C/L (9.20%), D67N/G (8.13%), V106M (9.13%) and K101Q/E (7.64%). For all strains carrying drug-resistance mutations, 19.56% were resistant to non-nucleoside RT inhibitors (NNRTIs) alone, 0.74% were resistant to nucleoside RT inhibitors (NRTIs) alone, and 11.44% were dual-resistant to both NRTIs and NNRTIs. Re sistance to 3TC, emtricitabine, efavirenz, etravirine, and NVP was seen in 10.70%, 10.70%, 28.04%, 7.75%, and 26.20% of strains, respectively (Figure 1). Resistance to the other five drugs (abacavir, AZT, stavudine, didanosine, and rilpivirine) was present in less than 10% of strains for each.
Resistant to nucleoside reverse transcriptase inhibitors
Frequency(%)Resistant to non-nucleoside reverse transcriptase inhibitors
Frequency(%)Mutation ART naive
(n=104)ART failure
(n=271)Mutation ART naive
(n=104)ART failure
(n=271)M41L 0.00 2.45 V90I 0.00 1.96 D67N/G 0.00 8.13 K101Q/E 0.00 7.64 T69S/A 0.00 2.45 K103N 0.00 45.01 K70R 0.00 4.28 V106M 0.00 8.13 M184V/I 0.00 35.88 E138A 0.00 1.00 T215Y/I 0.00 4.28 V179D/E 0.00 6.80 K219E 0.00 4.28 Y181C 0.00 17.33 Y188C/L 0.00 9.20 G190S/A 0.00 15.88 H221Y 0.00 1.44 P225H 0.00 1.00 F227L 0.00 1.44 K238 0.00 2.84 Abbreviation: ART, antiretroviral therapy. Table 2. Drug-resistance mutations in the current populations among HIV variants epidemic in Sichuan province
-
Since no transmission of drug resistance was found in ART-naive individuals in our study, we used the pol sequences identified from ART-naive individuals as a control background to explore potential drug-resistance-related mutations that are not included in the HIV Drug Resistance Database. Variations in the ancestor/consensus CRF07_BC sequences isolated from the therapy-naive and ART-failure groups were compared. No variations at the protease region were identified between the ART-naive and ART-failure groups. However, seven mutations at six RT amino acid sites (E28K, K32E, T35M, T200A, E248V, E248D, and K249Q) were found in the ART-failure group, with higher frequencies compared with the ART-naive group (Table 3).
Position Wild type
(aa)Mutation
(aa)Frequency(%) χ2 p-value ART naive ART failure 28 E K 0.00 14.02 – – 32 K E 1.90 15.50 13.37 < 0.01 35 T M 1.90 7.94 3.96 < 0.05 200 T A 4.76 12.92 5.18 < 0.05 248 E V 0.00 10.70 – – 248 E D 0.00 2.58 – – 249 K Q 0.00 13.28 – – Abbreviation: ART, antiretroviral therapy. Table 3. DrugMutations with significantly different distributions in the reverse transcriptase region between the therapy-naive (n=104) and ART-failure populations (n=271)